{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:26:10Z","timestamp":1778261170825,"version":"3.51.4"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>This report aims to better define the rare adverse event of immune checkpoint inhibitor-associated diabetes mellitus(ICI-DM). We present 10 cases of patients including six of the patients had no prior history of diabetes, while four had varying degrees of pre-existing diabetes. Eight who received anti-PD-1 combination therapy, one who received anti-PD-1 monotherapy, and one who received dual anti-PD-1\/CTLA-4 therapy. The mean time from initiation of immunotherapy to the onset of ICI-DM was 245.4 days (median, 149 days; range, 11 to 787 days). Diabetic ketoacidosis (DKA) occurred in 60% (6\/10) of the patients, with a median fasting blood glucose level of 25.85 mmol\/L (range, 14.76 to 38.23 mmol\/L), and all had C-peptide levels below the normal range. Through a retrospective analysis of the clinical data of these 10 patients, we found that monitoring fasting blood glucose and HbA1c is crucial for patients undergoing or having undergone immunotherapy, as rapid pancreatic \u03b2-cell destruction can be observed in those who develop ICI-DM, potentially due to disruption of the PD-1\/PD-L1 pathway.<\/jats:p>","DOI":"10.3389\/fendo.2025.1589630","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:10:22Z","timestamp":1751602222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitor-associated diabetes mellitus: the case series report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuhong","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianwen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3969\/j.issn.1673-9701.2024.31.026","article-title":"Advances in clinical research on immune checkpoint inhibitor-associated diabetes mellitus","volume":"62","author":"Chen","year":"2024","journal-title":"China Modern Doctor"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Hormone Metab Res = Hormon und Stoffwechselforschung = Hormones Metabolisme"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13604","article-title":"Onset of fulminant type\u20091 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy","volume":"12","author":"Boswell","year":"2021","journal-title":"A Case Rep J Diabetes Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000218","article-title":"Diabetes and blood glucose disorders under anti-PD1","volume":"41","author":"Magis","year":"2018","journal-title":"J Immunother (Hagerstown Md.: 1997)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-6187.2022.07.009","article-title":"Clinical characteristics and HLA genotype analysis of 8 cases of immune checkpoint inhibitor associated diabetes mellitus","volume":"30","author":"Liu","year":"2022","journal-title":"Chin J Diabetes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3969\/j.issn.1002-266X.2024.06.024","article-title":"Research progress on clinical characteristics and pathogenesis of immune checkpoint inhibitor-associated diabetes mellitus","volume":"4","author":"Zheng","year":"2024","journal-title":"Shandong Med J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3969\/J.issn.1672-6780.2024.04.031","article-title":"A review of immune checkpoint inhibitor-associated diabetes mellitus","volume":"27","author":"Zhang","year":"2024","journal-title":"China J Clin Healthe"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-1264.2023.05.16","article-title":"A series report of four cases of immune checkpoint inhibitor-induced diabetes mellitus and literature review","volume":"13","author":"Yang","year":"2023","journal-title":"Anti-tumor Pharm"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1589630\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:10:26Z","timestamp":1751602226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1589630\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":16,"alternative-id":["10.3389\/fendo.2025.1589630"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1589630","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"article-number":"1589630"}}